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ABSTRACT
Objectives: To compare the prevalence and intensity of adverse drug reactions (ADR) in patients receiving antiepileptic monotherapy and polytherapy, 
and to assess the pattern of depression associated with the therapy.
Methods: This is a prospective observational study conducted in neurology outpatient department for a time period of 6 months in a tertiary care 
hospital, South India. Patients diagnosed as epileptic for more than 6 months and receiving stable doses of antiepileptic drugs (AED) for 3 months 
were included in the study. Study participants receiving monotherapy and polytherapy were divided into groups. A detailed validated questionnaire 
was used to assess the incidence and severity of depression and ADRs among the study participants. Mann–Whitney test, Kruskal–Wallis test, and 
Wilcoxon signed rank test were used to know the statistical significance at p<0.05.
Results: Among 91 patients with epilepsy, depression was observed mainly in the study group receiving polytherapy than monotherapy. The severity 
of ADR observed among various study groups during the first and second visit were compared, which showed that all range of intensity scores were 
reported. During the second visit, the severity of ADR was high when compared to the first visit. Further incidence of ADRs with AED therapy was 
compared which showed clinically significant values in all ADRs reported in both monotherapy and polytherapy.
Conclusion: Our study showed, maximum ADRs were among the patients receiving polytherapy, and depression was observed in patients receiving 
polytherapy. This suggests the need for safe drug practice.
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INTRODUCTION
Epilepsy is a group of neurological disorders characterized by epileptic 
seizures [1]. About 1% of people worldwide (65 million) have epilepsy, 
and nearly 80% of cases occur in developing countries. In 2013, it 
resulted in 116,000 deaths up from 111,000 deaths in 1990 [2]. It is 
characterized by a tendency to recurrent seizures and is defined by two 
or more unprovoked seizures. In approximately 70% of patients with 
newly diagnosed epilepsy initial treatment with a single antiepileptic 
drug (AED) leads to complete seizure control without intolerable 
adverse effects. Unfortunately, monotherapy fails even at maximal 
tolerated doses in an important minority of patients. These patients 
usually have symptomatic epilepsies. For patients with refractory 
seizures, alternative monotherapy with a second-line agent is a very 
effective and well tolerated treatment policy. Approximately, 40% 
of patients with partial epilepsy that is refractory to one agent will 
benefit from alternative monotherapy. If alternative monotherapy fails, 
polytherapy with a combination of two drugs may be helpful in a small 
minority of patients. However, this efficacy is usually at the expense of 
added toxicity unless the daily dose of the first drug is reduced [3].
Although anticonvulsant polytherapy has been widely and traditionally 
used in the treatment of epilepsy, there is little evidence of its 
advantages over monotherapy. However, It does leads to problems of 
chronic toxicity, drug interactions, failure to evaluate individual drugs, 
and sometimes exacerbation of seizures. There are many causes of 
polytherapy which could be avoided by more careful monitoring and 
supervision of therapy [4].
AED treatment is required long-term, and it is potentially hazardous; it 
is important to choose agents on the basis of their adverse effect profile. 
Monotherapy in the management of seizure disorder is a laudable goal. 
Monotherapy typically reduces costs, reduces side effects and improves 
compliance. It also reduces drug-drug interactions, not only with other 
AEDs but also with other concomitant medications used in co-morbid 
illness. CNS side effects tend to be cumulative with centrally acting 
AEDs and thus adverse effects, such as drowsiness, ataxia, fatigue, or 
memory difficulties, are lessened with monotherapy [5]. Polytherapy 
with AEDs is not popular mainly because it is thought to be associated 
with more adverse effects and contribute relatively little in terms of 
efficacy compared with monotherapy [6].
Depressive disorders (DDs) are the most common type of psychiatric co-
morbidity in patients with epilepsy. The incidence of DDs in epileptics 
is estimated to be 30-70%. Despite their relatively high prevalence, DDs 
remain unrecognized and untreated in a large proportion of patients [7]. 
The decreased activity of serotonin, dopamine, and γ-aminobutyric acid 
facilitate; the kindling process of seizure foci, worsen seizure frequency 
and severity, and are reversed or blocked by AEDs. Decreased activities 
of these neurotransmitters are a pivotal pathogenic mechanism of 
DDs and form the basis of their pharmacotherapy. Thus, DDs and 
epilepsy may share common pathogenic mechanisms that facilitate the 
occurrence of one in the presence of other [7].
At present the undue toxicity, adverse drug reactions (ADRs) and 
inconvenient interactions are more common in polytherapy. Although 
monotherapy is universally accepted for treating early epilepsy, as 
many as 40% of patients will continue to have seizures and develop 
intolerable adverse effects.
There has been little demonstrable interest in devising systems in the 
occurrence of adverse events of AEDs in chronic epileptic patients in 
mono and polytherapy. We collected spontaneous complaints and 
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compared with a detailed semi-structured questionnaire. It is now 
widely accepted that the impact of epilepsy on the individual exceeds 
beyond the occurrence of seizures, and that there is a need for outcome 
measures sensitive to these consequences [8]. Hence, we measured the 
current depressive symptomatology and identified possible cases of 
DDs using the center for epidemiologic studies depression scale (CES-D) 
in epileptic patients. Furthermore, we assessed whether depression 
may aggravate the number and intensity of side effects in patients using 
AEDs. This study was aimed to compare the prevalence and intensity of 
ADR in patients receiving antiepileptic monotherapy and polytherapy, 
and to assess the pattern of depression associated with therapy.
METHODS
A prospective observational study was carried out over the duration of 
6 months from November, 2014 to April 2015 at Kovai Medical Center 
and Hospital (KMCH), Coimbatore, Tamil Nadu, India.
This study was approved by Institutional Ethics Committee. The data 
were collected from various sources such as patient’s case reports, 
treatment charts, and patient’s laboratory investigation and also 
through direct patient interview. The diagnosis of epilepsy was 
confirmed in every patient by computed tomography and/or magnetic 
resonance imaging scan reports. Other necessary data such as lab 
investigations and drugs prescribed were collected. Study participants 
and their relatives were clearly explained regarding the study and 
informed consent were collected from them.
The study participants irrespective of their gender diagnosed for 
epilepsy at least 6 months and receiving stable dose of anti-epileptic 
drug for at least 3 months were included in the study. The patients 
below 5 years of age, uncertainty in diagnosis of epilepsy, cognitive 
impairment, febrile illness, and non-compliant patients were excluded 
from the study.
To assess the presence and severity of ADRs among the study groups 
treated with monotherapy and polytherapy during their first and second 
(after 3-4 months) visit a detailed semi-structured questionnaire was 
used. Further CES-D questionnaire [9] was used to assess depression 
status in the study group during their first visit. ADRs of the first and 
second visit were rated as 1-4 points, according to the scale [10]. The 
presence of probable depression (score > 15) according to the CES-D 
was differentiated into three groups according to the score:
a. If the score is 22 or higher, the patient may be suffering from a major 
depression,
b. If the score is 15-21, the patient may be suffering from mild to 
moderate depression,
c. If the score is below 15, the test does not indicate that the patient is 
depressed.
Statistical analysis was performed using Mann–Whitney test, 
Kruskal–Wallis test and Wilcoxon Signed Rank test to know the level 
of significance as (p<0.05). Questionnaires were validated by using 
Cronbach α reliability coefficient.
RESULTS
A total of 91 epileptic patients who visited neurology outpatient 
department of the hospital were included in the study. Among the study 
population, male (56.04%) population were comparatively high than 
female (43.96%) population.
Patients treated with AEDs were divided into two groups, one group 
receiving monotherapy (53.85%) and the other receiving polytherapy 
(46.15%). Further, the study group was categorized on the basis of 
the severity of depression, like absent, mild to moderate and major. 
Among patients treated with monotherapy most of them were without 
depression, followed by 10 (20.4%) males and 5 (10.2%) females with 
major depression and few of them 3 (6.12%) males and 4 (8.16%) 
females had mild to moderate depression. In 49 polytherapy patients, 
majority of 15 (35.71%) males and 11 (26.19%) females had major 
depression, followed by few patients without depression while the 
rest, 4 (9.52%) males and 3 (7.14%) females had mild to moderate 
depression.
The study group was further compared with the ADR intensity scored 
during first and second visits. Patients with depression (n=55) in their 
first visit, the majority of male and female fell in the ADR intensity 
score of 21-30 and least number had an intensity score of more than 
40 (Table 1). During the second visit, it was found that majority of male 
and female had an intensity score between 31 and 40 and none of them 
fell in 1-20 categories (Table 2). Patients without depression (n=36), 
during their first visit majority of males and females had an intensity 
score between 1 and 20 while none of them fell in 31-40 and more 
than 40 category (Table 1). In the second visit, majority of 10 (18.18%) 
males and 9 (25%) females scored between 21 and 30 while none of 
them fell in more than 40 category of ADR score (Table 2).
In our study, the severity of ADRs during the first visit in monotherapy 
patients showed those 6 patients with lack of concentration, 4 patients 
with emotional liability, and 1 patient each in tremor, dizziness and 
sleep disturbance had more frequent ADRs. Nearly 80% of patients 
reported absence of ADRs such as aggressiveness, anxiety, hair loss, 
skin reactions, diplopia, dyspepsia, gingival hypertrophy, somnolence, 
and memory impairment. Average of 6 and 4 patients reported rare and 
mild ADRs (Table 3).
Prescription of patients treated with polytherapy was analyzed for 
drug-drug interactions. Particularly in this group one major drug 
interaction between valproate and lamotrigine as observed. Nearly, 
33% polytherapy patients fell under moderate interactions. All data 
were analyzed by Kolmogorov–Smirnov test. Since all values were 
>0.05 (5% level) normality assumption was not met, so non-parametric 
tests like Mann–Whitney test and Kruskal–Wallis test were used for 
further analysis of data. Difference in ADRs between first and second 
visit was compared with sex, age, treatment, and depression. There was 
no significant difference between the groups at 5% level (Table 4).
Depression level was compared with sex, age and treatment within the 
study group. No significant difference was found between the sex ratio 
Table 1: Study population attributed to ADR according to the 








M (%) F (%) M (%) F (%)
1-20 5 (9.09) 3 (5.45) 13 (36.11) 11 (30.56)
21-30 13 (23.64) 11 (20) 6 (16.67) 6 (16.67)
31-40 12 (21.82) 8 (14.55) 0 (0) 0 (0)
>40 1 (1.82) 2 (3.64) 0 (0) 0 (0)
ADR: Adverse drug reactions
Table 2: Study population attributed to ADR according to the 








M (%) F (%) M (%) F (%)
1-20 0 (0) 0 (0) 4 (11.11) 5 (13.89)
21-30 10 (18.18) 9 (16.36) 10 (18.18) 9 (25)
31-40 16 (29.09) 9 (16.36) 4 (11.11) 3 (8.33)
>40 5 (9.09) 6 (10.91) 0 (0) 0 (0)
ADR: Adverse drug reactions
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at any age group. However, there was a highly significant difference 
between monotherapy and polytherapy in their depression level at 1% 
level (Table 5).
All questions were tested for reliability by using Cronbach “α” reliability 
coefficient. It was found that α = 0.9649 for depression questionnaire 
and α = 0.8092 for ADR questionnaire and the questionnaires were 
highly reliable. Wilcoxon Signed Rank test was used to compare ADRs. 
Highly significant difference was found in psychomotor agitation, 
anxiety and headache and most of the ADRs were significant at 5% level 
while comparing the first and second visits of patients treated with 
monotherapy, but there was no significant difference in diplopia and 
gingival hypertrophy. Further difference between the first and second 
visit of polytherapy patients were compared which showed a significant 
difference between most of the ADRs at 5% level, whereas no significant 
difference in fatigue, gingival hypertrophy, memory impairment and lack 
of concentration. There was no significant difference between fatigue, 
aggressiveness, hair loss, skin reactions, diplopia, gingival hypertrophy 
and somnolence. Remaining all ADRs showed significant difference 
between the first and second visit of monotherapy patients without 
depression. While patients with depression showed no significant 
difference in emotional liability, dyspepsia gingival hypertrophy, 
tremor, dizziness, somnolence and sleep between their first and second 
visit. Remaining all the ADRs had significant difference at 5% level.
In this study, differences in ADR’s between first and second visit is 
not showing any statistical significance, whereas depression level 
compared within the population showed high statistical significance 
(p=0.013). In comparison of ADR’s, such as fatigue, gingival hypertrophy, 
memory impairment, sleep disturbance, and lack of concentration, are 
not showing any statistically significant relation to monotherapy and 
polytherapy.
When compared the ADRs of polytherapy patients without depression 
between their first and second visit, it was highlighted that only 
somnolence had a significant difference at 5% level. However, 
patients with depression showed no significant difference in fatigue, 
aggressiveness, anxiety, gingival hypertrophy, memory impairment, 
sleep disturbance, and lack of concentration. All other ADRs showed 
significant difference during both the visits (Table 6).
DISCUSSION
Choice of the initial AEDs is based on various factors such as age, sex, 
and type of seizure. Chronic use of AEDs may be associated with several 
systemic and CNS ADR [11]. Monotherapy in the management of seizure 
disorders is a laudable goal. Prior studies showed a reduction in drug-
drug interaction not only with AEDs but also with other concomitant 
medications used in co-morbid conditions [5]. Polytherapy with AEDs 
is not popular mainly because it is thought to be associated with more 
adverse effects and to contribute relatively little in terms of efficacy 
compared with monotherapy [6].
Earlier studies on safety of AEDs found that second generation newer 
AEDs produce rare idiosyncratic reactions [12]. Researchers have 
noted a higher incidence of depression among patients with epilepsy 
than the general population or others with chronic conditions such as 
hypertension and diabetes. For long-time, depression was thought to be 
Table 3: Severity of ADR on first visit and second visit
ADRs Number of subjects (n=49)
First visit Second visit
Absent Rare Mild Frequent Absent Rare Mild Frequent
Emotional liability 26 11 8 4 30 7 17 5
Fatigue 38 4 7 0 33 4 7 5
Psychomotor agitation 34 9 6 0 28 8 7 6
Aggressively 46 2 1 0 42 5 1 1
Anxiety 41 5 3 0 28 10 7 4
Headache 36 7 5 0 26 7 12 4
Hair loss 42 5 2 0 39 4 5 1
Skin reactions 41 8 0 0 39 5 5 0
Diplopia or blurred vision 43 6 0 0 43 2 2 2
Dyspepsia 40 6 3 0 34 2 11 2
Gingival hypertrophy 46 1 2 0 45 1 3 0
Tremor 36 6 6 1 32 6 7 4
Weight gain 36 9 4 0 31 4 12 2
Dizziness 31 7 10 1 27 4 10 8
Somnolence 43 1 5 0 40 1 3 5
Memory impairment 40 7 2 0 30 9 6 4
Sleep disturbance 30 11 7 1 27 7 8 7
Lack of concentration 26 11 6 6 20 6 11 12
ADR: Adverse drug reactions
Table 4: Difference in ADRs between first and second visit 
compared with in the study population
Factors Groups Number p value
Sex Male 51 0.749
Female 40




60 and above 3
Treatment Monotherapy 49 0.784
Polytherapy 42
Depression Without depression 36 0.522
With depression 55
ADR: Adverse drug reactions
Table 5: Depression level compared within the study population
Factors Groups Number p value
Sex Male 51 0.396
Female 40




60 and above 3
Treatment Monotherapy 49 0.000**
Polytherapy 42
**Highly significant at 1% level
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a complication of epilepsy. People with a history of depression have a 
3-7 times higher risk of developing epilepsy [7].
Although standard AEDs (first generation) are effective in achieving 
complete seizure control in the majority of patients, an appreciable 
proportion is at least in part resistant to conventional pharmacotherapy. 
The paper reviews strategies to incorporate new AEDs (second 
generation) into the treatment arsenal for patients with epilepsy [13]. 
In our study group, we discussed the basis of reasoned polytherapy and 
some of the possible interactions between AEDs. The drug interactions 
between AEDs themselves and with other drugs are frequent but not 
usually of clinical importance [10].
Epileptic seizures and epileptic syndromes have high prevalence 
and incidence rates affecting all ages and all races of both sexes. It 
is estimated that 50 million people live with epilepsy, 80% of whom 
reside in developing countries. AED broadly used today have a number 
of ADRs including a propensity for drug interactions. Depression 
is the most common type of psychiatric co-morbidity in patients 
with epilepsy. The drug interactions between the AEDs themselves 
are frequent but not usually of clinical importance. ADRs are highly 
prevalent when a detailed questionnaire is applied. Aggravation of the 
number and intensity of ADRs have no relationship with depression. 
By our study the recommendations we put forward are: To inform 
all patients about ADRs that is not uncommon especially in the first 
2 months, to perform controlled studies for elucidating the specific 
weakness of monotherapy and polytherapy, to assess the strengths of 
second generation AEDs compared with the first generation and finally 
to develop a pragmatic approach until evidence-based choice can be 
made for choosing monotherapy and polytherapy.
CONCLUSION
Once diagnosed, epileptic patients have to take AEDs for almost entire 
life, thus safety of AED is much questioned. A number of AED is broadly 
used today and have a number of ADRs in which depression is the most 
common type of psychiatric co-morbidity in patients with epilepsy. 
From our study, it is concluded that the level of depression as well as 
ADR was higher in patients receiving polytherapy than monotherapy. 
Thus, we recommend that more studies are needed to elucidate the 
specific weakness of monotherapy and polytherapy, and strengths 
of second generation AEDs compared with the first generation, All 
patients has to be informed about ADRs that are not uncommon 
specially in the first 2 months and a more realistic approach is needed 
until an evidence-based choice can be made for choosing monotherapy 
and polytherapy keeping patient safety in mind.
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ADRs Monotherapy Polytherapy
Without depression With depression Overall Without depression With depression Overall
Emotional liability 0.009* 0.084 0.002* 0.317 0.046* 0.034*
Fatigue 0.785 0.004* 0.012* 1.000 0.157 0.157
Psychomotor agitation 0.034* 0.003* 0.000** 0.317 0.046* 0.025*
Agressivity 0.157 0.046* 0.014* 0.180 0.102 0.038*
Anxiety 0.004* 0.020* 0.000** 0.102 0.059 0.013*
Headache 0.007* 0.007* 0.000** 0.083 0.002* 0.001*
Hair loss 0.180 0.025* 0.011* 1.000 0.046* 0.046*
Skin reactions 0.317 0.014* 0.008* 0.157 0.007* 0.002*
Diplopia or blurred vision 0.317 0.038* 0.084 0.317 0.003* 0.002*
Dyspepsia 0.025* 0.052 0.005* 0.059 0.011* 0.002*
Gingival hypertrophy 1.000 0.414 0.414 0.317 1.000 0.317
Tremor 0.038* 0.102 0.008* 1.000 0.015* 0.015*
Weight gain 0.039* 0.046* 0.005* 1.000 0.004* 0.004*
Dizziness 0.016* 0.145 0.006* 0.180 0.004* 0.002*
Somnolence 0.066 0.317 0.041* 0.038* 0.039* 0.004*
Memory impairment 0.041* 0.008* 0.001* 1.000 1.000 1.000
Sleep disturbance 0.026* 0.238 0.015* 1.000 0.063 0.063*
Lack of concentration 0.024* 0.011* 0.001* 0.317 0.317 0.180
*Significant at 5% level, **Highly significant at 1% level, ADR: Adverse drug reactions
